Abacavir + Dolutegravir + LamivudineThird Party Manufacturing in India

Abacavir + Dolutegravir + Lamivudine works as a potent combination therapy to suppress HIV replication.

Abacavir and Lamivudine are Nucleoside Reverse Transcriptase Inhibitors (NRTIs) that block the reverse transcriptase enzyme, preventing the virus from converting its RNA into DNA. Dolutegravir is an Integrase Strand Transfer Inhibitor (INSTI) that stops the viral DNA from integrating into the host cell's genetic material.

Unlike single-drug treatments, this triple-action combination prevents viral resistance by targeting multiple stages of the HIV lifecycle simultaneously. It is highly effective and well-tolerated for long-term management of HIV-1 infection.

Therapeutic Uses

Abacavir + Dolutegravir + Lamivudine is prescribed for the treatment of:

• HIV-1 Infection: Used as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) in adults and pediatric patients.
• Viral Load Suppression: Highly effective in reducing and maintaining an undetectable viral load.

Why Manufacturers Choose This Combination

This antiretroviral formulation represents a gold standard in modern HIV care, offering high efficacy with a simplified once-daily dosing regimen. Its clinical success has driven immense demand in both domestic and international markets, particularly for export to developing regions.

This makes the combination one of the most sought-after products for third party manufacturing in India, with consistent demand from export-oriented companies involved in global health programs.